Last Updated: June 24, 2026

Litigation Details for Wilus Institute of Standards and Technology Inc. v. HP Inc. (E.D. Tex. 2024)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Wilus Institute of Standards and Technology Inc. v. HP Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation Summary and Analysis: Wilus Institute of Standards and Technology Inc. v. HP Inc. (E.D. Texas, 2:24-cv-00752)

Last updated: June 24, 2026

Wilus Institute of Standards and Technology Inc. sued HP Inc. in the U.S. District Court for the Eastern District of Texas under case number 2:24-cv-00752. The available record in the prompt does not include the asserted patents, claims, accused HP products, claim charts, venue transfer posture, early injunction efforts, or any filed claim-construction or motion practice. Without those litigation specifics, a complete patent-litigation analysis (validity, infringement theory, strength of estate, schedule, settlement posture, and generic/competition impact) cannot be produced accurately.

What claims and patents does Wilus Institute of Standards and Technology Inc. assert against HP Inc. in 2:24-cv-00752?

No patent numbers, asserted claims, or infringement allegations are provided in the prompt. A litigation summary without the asserted patent portfolio is incomplete and cannot be made accurate.

Which HP products are accused?

No accused products or technical identifiers are provided in the prompt.

Is the case about hardware, software, or network printing/document workflows?

No allegation category is provided in the prompt.

What is the procedural posture of Wilus Institute of Standards and Technology Inc. v. HP Inc. (2:24-cv-00752)?

No docket milestones are provided in the prompt (complaint filing date, service date, Rule 12 motions, Rule 16 scheduling order, infringement contentions, invalidity contentions, Markman date, summary judgment dates, or trial date). A posture analysis would require docket facts that are not present.

Has HP filed a motion to dismiss, transfer venue, or challenge standing?

No motion practice details are provided in the prompt.

Has the court issued a scheduling order or set a Markman date?

No scheduling facts are provided in the prompt.

How strong is Wilus’s patent case against HP based on the pleaded theories?

The prompt does not include:

  • asserted patents and their publication or priority dates,
  • claim construction positions,
  • accused claim mapping,
  • prior art references invoked,
  • or asserted damages theory.

Without those elements, infringement and validity strength cannot be assessed in a way that would meet an evidence-based litigation standard.

Does the complaint target active claims construction issues?

No claim-construction focus is provided in the prompt.

Are there likely design-around or non-infringement defenses based on product architecture?

No product architecture facts are provided in the prompt.

When does the infringement theory implicate patent expiration or terminal disclaimer timing?

No patent expiration data, maintenance status, or terminal disclaimer facts are provided in the prompt. Any exclusivity or expiration timing analysis would be speculative.

What validity risks does HP face if Wilus asserted method, system, or computer-implemented claims?

No asserted claim types are provided in the prompt. Validity exposure depends on claim category and recited elements, which are not present.

How does §101, §102, §103, or §112 risk differ by claim scope?

No claim language or mapping is provided in the prompt.

What damages and injunction risks are at issue in 2:24-cv-00752?

No damages model, royalty rate contentions, demand for injunctive relief, or eBay factors are provided in the prompt.

Is Wilus seeking a preliminary injunction?

No request for preliminary relief is provided in the prompt.

What is the likely damages framework (reasonable royalty, lost profits, or enhanced damages)?

No damages allegations are provided in the prompt.

Are there related cases, prior settlements, or continuation filings that affect strategy?

No related-case identifiers, earlier disputes, or family continuations are provided in the prompt. Without those, cross-case strategy and estoppel analysis cannot be performed.

What is the litigation impact for HP’s product roadmap and downstream customers?

No accused product scope is provided in the prompt. Business impact analysis depends on which product lines are accused, affected regions, and the likelihood of design changes.

Key Takeaways

  • The prompt provides only the parties and docket number: Wilus Institute of Standards and Technology Inc. v. HP Inc., 2:24-cv-00752.
  • It does not provide asserted patent numbers, accused HP products, pleaded claims, docket milestones, motion practice, or any orders.
  • A complete litigation summary and analysis cannot be produced accurately with the information given.

FAQs

1) What is the asserted patent list for Wilus v. HP in 2:24-cv-00752?
Not provided in the prompt.

2) What HP products are accused in 2:24-cv-00752?
Not provided in the prompt.

3) Has HP filed a motion to dismiss or transfer venue in 2:24-cv-00752?
Not provided in the prompt.

4) Has the court set a Markman hearing date or claim construction schedule in 2:24-cv-00752?
Not provided in the prompt.

5) Is injunctive relief sought or likely in 2:24-cv-00752?
Not provided in the prompt.

References

No sources are provided in the prompt.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.